KPV Peptide COA: Verify a Vial Before You Pay

For research use only. Not for human or animal consumption.


What it is

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone: residues 11 to 13, lysine-proline-valine, in that order. Three residues, roughly a quarter the mass of a 13-residue peptide hormone — and that small size drives most of the analytical questions below.

The identity a genuine vial has to match:

  • Chemical name: KPV (Lys-Pro-Val, alpha-MSH 11-13)
  • CAS number: 67727-97-3
  • Molecular formula: C16H30N4O4
  • Molecular weight: 342.43
  • Form: lyophilised powder
  • Storage: −20 °C, desiccated, protected from light

Cross-checked against PubChem CID 125672: the same formula, the same 342.43, the same CAS number for Lys-Pro-Val, monoisotopic mass 342.2267.

A 2010 review chapter records that this tripeptide lacks the entire sequence motif required for binding to any known melanocortin receptor, while remaining the C-terminal fragment of the parent hormone [7]. Investigators have therefore examined intracellular targets rather than receptor occupancy.

Clarion publishes a release specification of >99 % by HPLC main peak with identity confirmed by mass spectrometry, and maintains a public lot ledger in which a lot number resolves to that lot’s own signed third-party certificate.

What researchers are studying

The corpus is small and almost entirely preclinical — immortalised human cell lines and mouse models. No published human clinical study of this tripeptide itself was located.

Transporter uptake. Dalmasso and colleagues, in Gastroenterology (2008), characterised uptake of radiolabelled tripeptide through the di- and tripeptide transporter PepT1 in human intestinal epithelial lines (Caco2-BBE, HT29-Cl.19A) and a T-cell line (Jurkat), competing it against a known PepT1 substrate, then extended the work into two chemically induced mouse intestinal models, DSS and TNBS, at the amounts described in the paper [1].

Signalling without a melanocortin receptor. Land, in the International Journal of Physiology, Pathophysiology and Pharmacology (2012), measured NF-kappaB reporter activity and chemokine secretion in a human bronchial epithelial line (16HBE14o-), describing an interaction between the tripeptide and the importin-alpha3 binding site on p65RelA, stabilisation of IkappaB-alpha, and less nuclear translocation of tagged p65RelA than in control [3]. That journal is a low-impact open-access title. The 2010 review states that the signalling mechanism used by this tripeptide is not established [7].

Second messengers in skin cells. Elliott and colleagues, in the Journal of Investigative Dermatology (2004), detected no cyclic AMP elevation in HaCaT or normal human keratinocytes exposed to the tripeptide, and measured rapid intracellular calcium changes instead. The study ran an all-L form and a D-valine variant side by side — directly useful for identity work [2].

Antimicrobial screening, then a contradiction. Cutuli and colleagues, in the Journal of Leukocyte Biology (2000), ran colony-formation assays against Staphylococcus aureus and germ-tube assays against Candida albicans and reported inhibition across a range of concentrations [4]; a comment and author reply in the same journal mark it as contested. Eighteen years on, Songok and colleagues, in PLoS One, assayed an N-acetylated, C-amidated form and glycoalkylated analogues and reported no activity, noting stability toward proteolytic enzymes [5]. The two groups did not test identical molecules, so neither result settles the other.

Analogue and dimer chemistry. Catania and colleagues, in the Journal of Peptide Research (2005), inserted a Cys-Cys linker between two copies of the tripeptide and solved the dimer’s solution structure by proton NMR, describing an extended backbone with a beta-turn-like element [6]. The other synthetic-chemistry item is the 2018 glycoalkylation work on the lysine side-chain amine [5].

Much of the post-2015 record studies the tripeptide inside a hydrogel or nanoparticle carrier rather than the molecule directly. A PubMed query on the parent-hormone fragment designation returns fewer than thirty indexed records.

How to verify a vial before you pay

Start with the laboratory. The certificate for the current Clarion KPV lot is signed by Freedom Diagnostics Testing. Clarion assigns laboratories per lot, so the name that counts is the one on the certificate the lot number resolves to. A report naming no laboratory is not verification.

The lot number has to resolve to its own document. Clarion’s public lot ledger maps a lot number to that lot’s own signed certificate; a generic file, or one for another batch, says nothing about the vial in hand.

The specification is a method, not a verdict. The release specification is >99 % by HPLC main peak with identity confirmed by mass spectrometry. That pair establishes the mass of the principal component and how much of the ultraviolet-absorbing material it represents — not residue order, stereochemistry, counter-ion identity, water content or net peptide content.

Four questions this molecule raises that a larger peptide does not:

  1. Counter-ion mass. Synthesis and preparative HPLC normally leave a counter-ion on the two basic sites. One acetate adds about 60.05 to the formula mass, one trifluoroacetate about 114.02 — roughly 15 % and 25 % of a 342 g/mol backbone, against a rounding error on a 1400 g/mol peptide. Net peptide content comes from amino-acid analysis or nitrogen determination, counter-ion content from ion chromatography or fluorine NMR; an area-percent figure answers neither.
  1. No aromatic residue, so no 280 nm signal. Lysine, proline and valine carry no tryptophan, tyrosine or phenylalanine ring, so detection sits near the peptide-bond absorbance around 210 to 220 nm, where solvents, residual acids and scavengers also absorb. A clean main peak there can coexist with contaminants the detector barely registers.
  1. Isobaric sequence scrambles. Every permutation of the three residues shares one mass: Val-Pro-Lys, Pro-Lys-Val and Lys-Val-Pro are indistinguishable from Lys-Pro-Val by intact mass alone. Only sequence-confirming fragmentation, or amino-acid analysis against a reference standard, separates them — and residue order is the whole definition of a fragment named for its position in a hormone.
  1. Stereochemistry is invisible to mass spectrometry. The literature uses a D-valine variant alongside the all-L form; the 2004 keratinocyte study ran both [2]. Those molecules share a formula and a mass; chiral analysis or co-elution against a characterised standard tells them apart.

Names that are not this molecule. The Cys-Cys-linked dimer solved in 2005 [6] has a different mass and is sometimes sold under a name that reads like a variant. A separate tripeptide in the 2010 review chapter, from an interleukin-1 beta sequence, differs by one residue [7]. The parent hormone is a third item.

Where researchers source it. Any supplier worth paying answers three questions in writing first: which laboratory signed the certificate, which methods were run, and whether the lot number resolves to that lot’s own document rather than a generic file. Clarion answers all three on the product page and in the public lot ledger.

Common questions

What is KPV, in one line? The C-terminal tripeptide of alpha-melanocyte-stimulating hormone, Lys-Pro-Val, CAS 67727-97-3, a lyophilised powder for research use only.

Which laboratory signed the certificate? For the current Clarion lot, Freedom Diagnostics Testing. Clarion assigns laboratories per lot and publishes the certificate each lot resolves to.

Does mass-spectrometric identity confirmation prove the sequence? No. Intact mass cannot separate Lys-Pro-Val from any other permutation of the same three residues, nor an all-L form from a D-valine variant.

Why does the vial look nearly empty? A few milligrams of a 342 g/mol powder forms a thin film, not a visible plug. Fill mass is confirmed by documentation, not by eye, and stays so after dissolving the powder.

How should it be stored? At −20 °C, desiccated and protected from light.

Is this a medicine? No — a research-use-only material, not for human or animal consumption.

References

Re-verified 2026-08-20 against NCBI E-utilities, three cross-checked in Europe PMC; chemistry against PubChem CID 125672. Two titles omitted; identifiers given in full.

  1. Dalmasso G et al. Gastroenterology 2008;134(1):166-78. PMID 18061177 · DOI 10.1053/j.gastro.2007.10.026 · PMCID PMC2431115. Title omitted.
  1. Elliott RJ et al. “alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.” *Journal of Investigative Dermatology* 2004;122(4):1010-9. PMID 15102092 · DOI 10.1111/j.0022-202X.2004.22404.x
  1. Land SC. International Journal of Physiology, Pathophysiology and Pharmacology 2012;4(2):59-73. PMID 22837805 · PMCID PMC3403564 (no DOI registered). Title omitted.
  1. Cutuli M et al. “Antimicrobial effects of alpha-MSH peptides.” Journal of Leukocyte Biology 2000;67(2):233-9. PMID 10670585 · DOI 10.1002/jlb.67.2.233. Comment and author reply in the same journal, 2009;85(3):371-2.
  1. Songok AC et al. “Structural modification of the tripeptide KPV by reductive ‘glycoalkylation’ of the lysine residue.” PLoS One 2018;13(6):e0199686. PMID 29953505 · DOI 10.1371/journal.pone.0199686 · PMCID PMC6023233
  1. Catania A et al. “Three-dimensional structure of the alpha-MSH-derived candidacidal peptide [Ac-CKPV]2.” Journal of Peptide Research 2005;66(1):19-26. PMID 15946192 · DOI 10.1111/j.1399-3011.2005.00265.x
  1. Brzoska T et al. Advances in Experimental Medicine and Biology 2010;681:107-16. PMID 21222263 · DOI 10.1007/978-1-4419-6354-3_8. Review chapter.

Related: How to verify a peptide certificate of analysis.

KPV (Lys-Pro-Val, alpha-MSH 11-13), CAS 67727-97-3, C16H30N4O4, MW 342.43. Release specification >99 % HPLC main peak with mass-spectrometric identity; the current lot’s certificate is signed by Freedom Diagnostics Testing. For research use only. Not for human or animal consumption. Not a drug.